Skip to main content
HR 5729 113th Congress House

Adding Ebola to the FDA Priority Review Voucher Program Act

Official title: To expand the program of priority review to encourage treatments for tropical diseases.

Introduced: November 18, 2014 Introduced by: Blackburn, Marsha Republican · Tennessee See on congress.gov
Health Drug safety, medical device, and laboratory regulationDrug therapyInfectious and parasitic diseases
Sign in to write a letter Sign in to watch
This bill died when the 113th Congress ended
It never became law before the 113th Congress (2013–2014) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Nov 21, 2014
Referred to the Subcommittee on Health.
Nov 18, 2014
Referred to the House Committee on Energy and Commerce.
Nov 18, 2014
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action November 21, 2014

Referred to the Subcommittee on Health.

 Plain-English summary Congressional Research Service

Adding Ebola to the FDA Priority Review Voucher Program Act - Amends the Federal Food, Drug, and Cosmetic Act to add filoviruses, a family of viruses that includes the Ebola virus, to the list of tropical diseases under the priority review voucher program, which awards vouchers to sponsors of human drug applications that are approved to prevent or treat tropical diseases. (A voucher entitles the holder to have a future human drug application acted upon by the Food and Drug Administration (FDA) within six months.)

Changes the process by which infectious diseases that do not significantly impact developed nations and disproportionately affect poor and marginalized populations can be designated as tropical diseases from rulemaking to order of the Secretary of Health and Human Services (HHS).

Allows priority review vouchers to be transferred between sponsors of human drug applications any number of times.

Reduces from 365 days to 90 days the advance notice required before submitting a human drug application subject to a priority review voucher.
 Related & companion bills 1
  • S 2917 Identical bill Adding Ebola to the FDA Priority Review Voucher Program Act
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 4
All 4 Republican 2
Butterfield, G. K.
· Nov 18, 2014
 R
Fleischmann, Charles J. "Chuck"
Tennessee · Nov 18, 2014
GREEN, GENE
· Nov 18, 2014
 R
McCaul, Michael T.
Texas · Nov 18, 2014
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 5729: Adding Ebola to the FDA Priority Review Voucher Program Act. 113th Congress. Open America. https://openamerica.io/bill/113-HR-5729/
MLA
"H.R. 5729: Adding Ebola to the FDA Priority Review Voucher Program Act." 113th Congress, 2026, Open America, https://openamerica.io/bill/113-HR-5729/.
Bluebook (legal)
H.R. 5729, 113th Cong. (2026), https://openamerica.io/bill/113-HR-5729/.
Markdown link
[H.R. 5729: Adding Ebola to the FDA Priority Review Voucher Program Act](https://openamerica.io/bill/113-HR-5729/)
Report a problem